Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VENT-03 in Cutaneous Lupus Erythematosus
NCT07260877Phase 2Active, not recruiting
- Sponsor
- Ventus Therapeutics
- Start
- Dec 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of VENT-03 in cutaneous lupus erythematosus (CLE), sponsored by Ventus Therapeutics. Started Dec 2025; status: active, not recruiting.
02
Drugs
VENT-03
03
Conditions
cutaneous lupus erythematosus (CLE)
Beyond the preview
Go deeper on NCT07260877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260877.